12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

CYT387: Completed Phase I/II enrollment

YM BioSciences disclosed in its earnings for 1Q12 ending Sept. 30 that it completed enrollment of 166 patients in an open-label, international Phase I/II trial evaluating CYT387. The open-label, dose-escalation Phase I portion of the trial determined the MTD...

Read the full 173 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >